Development and validation of LC‐MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study

摘要

Abstract A simple and highly sensitive liquid chromatography–tandem mass spectrometry (LC‐MS/MS) bioanalytical method was developed and fully validated for the first time for the simultaneous determination of newly discovered antiviral drugs, namely sofosbuvir (SOF) and daclatasvir (DAC) in human plasma. Tadalafil (TAD) was used as internal standard (IS). SOF, DAC and TAD (IS) were extracted from plasma using liquid–liquid extraction technique with methyl tert ‐butyl ether. The chromatographic separation was carried out using ZorbaxSB‐C 18 column (4.6 × 50?mm,5?μm) and 5?m m ammonium formate buffer (pH?3.5)–acetonitrile (50:50, v/v) as mobile phase in an isocratic elution mode pumped at a flow rate 0.7?mL min ?1 . The quantitation was performed on API4500 triple quadrupole tandem mass spectrometer with positive electrospray ionization interface in multiple reaction monitoring mode. Validation was applied according to US Food and Drug Administration guidelines for bio‐analytical methodswith respect to linearity, precision, accuracy, selectivity, carry‐over, stability and dilution integrity. Linearity was obtained over concentration ranges of 0.3–3000 and 3–3000?ng mL ?1 for SOF and DAC, respectively, by applying a weighted least‐squares linear regression method (1/ x 2 ). The proposed method could be applied successfully in bioequivalence and/or clinical studies for therapeutic drug monitoring of patients undergoing dual combination therapy as the latter combination proved more efficacious and powerful tool for the complete treatment of hepatitis C genotype 3 within 16?weeks. The suggested method has been applied successfully to pharmacokinetic studies with excellent assay ruggedness and reproducibility.